Industry

CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–$KALV–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2022 European Academy of Allergy and Clinical Immunology (EAACI) Congress, taking place in Prague, Czech Republic and virtually, … [Read more…]

LifeWorks Mental Health Index™ reveals 20 percent of Americans are unable to meet basic needs due to inflation CHICAGO–(BUSINESS WIRE)–LifeWorks, a leading provider of digital and in-person total wellbeing solutions, today released its monthly Mental Health Index™ showing that the 20 percent of Americans who are not able to meet basic needs, such as food … [Read more…]

Company will pursue untapped opportunities in the field of innate immune system checkpoints to eliminate cancer Proprietary platform leverages CRISPR screening and macrophage biology to systematically discover and drug “don’t eat me” (DEM) and “eat me” (EM) signals CAMBRIDGE, Mass.–(BUSINESS WIRE)–DEM BioPharma, Inc. (DEM Bio), an immuno-oncology company developing therapies that target novel innate immune … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Double Homeobox Protein 4 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. Double Homeobox Protein 4 (Double Homeobox Protein 10 or DUX4) Drugs in Development report provides in depth analysis on Double Homeobox Protein 4 (Double Homeobox Protein … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Growth Opportunities in Military Medical Device Technologies” report has been added to ResearchAndMarkets.com’s offering. Over the years, the healthcare industry has developed several unique technologies for emergency medical services and critical care. An important user of critical care healthcare products is the military or the defense forces. Advanced medical technologies have improved the … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “T Cell Specific Surface Glycoprotein CD28 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players” report has been added to ResearchAndMarkets.com’s offering. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. … [Read more…]

LYON, France–(BUSINESS WIRE)–Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has secured EUR 10M from Bpifrance to support the further clinical development of OVX836, its lead broad-spectrum influenza vaccine candidate. The grant financing is part of the Healthcare Innovation 2030 plan by … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “U.S. House Calls Market Size, Share & Trends Analysis Report by Service (Primary Care, Urgent Care, Preventive Care, Mobile Clinical Testing, Chronic care Management) and Segment Forecasts, 2022-2030” report has been added to ResearchAndMarkets.com’s offering. The U.S. house calls market size is expected to reach USD 831.2 million by 2030 expanding at a … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Research Antibodies and Reagents Global Market Report 2022: By Technology, By Application, By End-User” report has been added to ResearchAndMarkets.com’s offering. Research Antibodies and Reagents Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global research antibodies and reagents market. This report … [Read more…]

GENT, Belgium & TOKYO–(BUSINESS WIRE)–H.U. Group Holdings Inc., and its wholly-owned subsidiary Fujirebio Holdings, Inc., and ADx NeuroSciences NV today announced the acquisition of ADx NeuroSciences by Fujirebio for 40 million euros. Pending the satisfaction of customary closing conditions, the deal is expected to close in July 2022. ADx NeuroSciences becomes a wholly owned subsidiary … [Read more…]